Articles related to DRUG SAFETY & INTERACTIONS

The FDA announced on April 30, 2026 it is considering removing GLP-1 receptor agonists from the 503B bulks list, with public comment open through the end of June 2026.

Eleven infants in Spain developed hypertrichosis in 2024 after secondary exposure to caregivers’ topical minoxidil, with symptoms resolving once exposure ended.

A single-institution case series of 13 biopsy-proven hydroxychloroquine cardiomyopathy patients documented variable outcomes after drug cessation, ranging from full functional recovery to progression requiring advanced heart failure therapies.

The American Academy of Ophthalmology updated hydroxychloroquine retinopathy screening recommendations, emphasizing dose limits, OCT and FAF as primary screening modalities, and risk stratification by renal status and concurrent tamoxifen use.

The FDA approved dextromethorphan-bupropion (Auvelity) for agitation associated with dementia due to Alzheimer’s disease, based on phase 3 trial data and a long-term randomized withdrawal study.

VMAT2 inhibitors were associated with lower rates of falls, injuries, fractures, and several secondary adverse outcomes than anticholinergic agents in a propensity-matched cohort of adults with tardive dyskinesia.